International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 1993
Norplant use by women with sickle cell disease.
СтатьяПоддержка исследования: вне правительства СШАПоддержка правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ladipo O A, Falusi A G, Feldblum P J, Osotimehin B O, Otolorin E O, Ojengbede O A
Аннотация
OBJECTIVE: To assess the safety of Norplant contraceptive implant use by women with mild-moderate homozygous sickle cell disease (HbSS).
METHOD: Prospective observation of women pre- and post-insertion of Norplant, with each woman serving as her own control.
PARTICIPANTS: 25 women 18-40 years of age who attended a hospital sickle cell clinic; post-insertion data were available for 23 women.
OUTCOME MEASURES: Changes in hematologic parameters including PCV, MCV, reticulocytes, ISCs, HbF and bilirubin; changes in biochemical parameters including HDL cholesterol, aspartate transaminase, alkaline phosphate, serum creatinine and serum albumin.
RESULT: With a mean follow-up of 12.4 months (range 1-29 months), there were no clinically or statistically significant group or individual changes in the hematologic or biochemical parameters after Norplant insertion.
CONCLUSION: Norplant appears to be a safe and appropriate contraceptive for women with mild-moderate HbSS disease.
METHOD: Prospective observation of women pre- and post-insertion of Norplant, with each woman serving as her own control.
PARTICIPANTS: 25 women 18-40 years of age who attended a hospital sickle cell clinic; post-insertion data were available for 23 women.
OUTCOME MEASURES: Changes in hematologic parameters including PCV, MCV, reticulocytes, ISCs, HbF and bilirubin; changes in biochemical parameters including HDL cholesterol, aspartate transaminase, alkaline phosphate, serum creatinine and serum albumin.
RESULT: With a mean follow-up of 12.4 months (range 1-29 months), there were no clinically or statistically significant group or individual changes in the hematologic or biochemical parameters after Norplant insertion.
CONCLUSION: Norplant appears to be a safe and appropriate contraceptive for women with mild-moderate HbSS disease.